PRISM MarketView Highlights Seven Small-Cap Lung Cancer Developers for Lung Cancer Awareness Month
Globe Newswire•16/11/2026•11:42 ET
1
Key Highlights
- ➤FDA rejects PD-1xVEGF bispecific after no statistically significant survival benefit
- ➤Candel (CADL) and MAIA (MAIA) run Phase 3 trials with overall survival endpoints
- ➤Cullinan (CGEM) and Taiho await FDA zipalertinib decision on February 27, 2027
- ➤Personalis (PSNL) secures Medicare coverage for NeXT Personal in stage I-III NSCLC
- ➤bioAffinity (BIAF) extends CyPath Lung testing to post-treatment survivor monitoring
NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- PRISM MarketView, a financial media platform covering small-cap public companies through 27 thematic indexes, today published a Lung Cancer Awareness Month feature on seven small-cap companies developing therapies and diagnostics for lung cancer, the leading cause of cancer death in the U.S.
The feature follows the FDA's decision not to approve a PD-1xVEGF bispecific antibody in EGFR-mutated lung cancer after the agency concluded the data could not establish effectiveness without a statistically significant survival benefit. The decision has put clinical endpoints in focus for smaller developers working in the disease.
Get started
Create a free account to read the full story.
